Telomir Pharmaceuticals spent the second quarter becoming a clinical-stage oncology name on paper while remaining a pre-enrollment company in practice. The Food and Drug Administration cleared an investigational new drug application for Telomir-Zn in advanced or metastatic triple-negative breast cancer at the end of April. That clearance is the entire equity story. What it is not is a funded, enrolling trial. Site activation is described as underway, yet a first-patient disclosure has not appeared, and research spending in the first half still looks like late preclinical work rather than a multi-center oncology start.
The capital structure is the binding constraint, not the science brochure. Cash at mid-year was $5.2 million. Operating cash use in the first half was $2.8 million. Management states existing cash funds operations only through early next year and raises substantial doubt about going concern. A related-party merger in April issued about thirty-four million shares and doubled the share count, booking a $46 million deemed dividend against a $1.0 million cash contribution. Bayshore Trust's $4.0 million milestone equity line and Starwood Trust's unused $5.0 million credit facility are the disclosed backstops. As of the mid-year statements, the Bayshore line had funded nothing.
The market is not pricing cash. At the September publication close the equity capitalized near eighty-five million against that cash pile, which means almost the entire enterprise value is a call on human data that does not yet exist. The question the next several months resolve is narrow. Does Telomir enroll the first triple-negative patient and convert paper related-party capacity into cash before the runway statement becomes an operating curtailment?